Top news of March: Effects of keto-style diet on the heart; bempedoic acid; and more
Click Here to Manage Email Alerts
Healio and Cardiology Today have aggregated the top cardiology headlines of March 2023.
Readers were most interested in the CV impact of a “keto-style” diet; the benefits of bempedoic acid in high-risk patients; the FDA’s decision on omecamtiv mecarbil for patients with heart failure with reduced ejection fraction; and more.
Image: Adobe Stock
‘Potential cardiovascular risk’ for some on keto-style diet
Certain traditional risk factors including severe high cholesterol, diabetes, hypertension and smoking may increase CV risk among those following a low-carbohydrate, high-fat “keto-style diet,” a speaker reported. Read more
Oral PCSK9 inhibitor lowers LDL similar to injection in short-term phase 2 trial
In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session. Read more
Bempedoic acid an ‘effective alternative’ for statin-intolerant patients: CLEAR Outcomes
In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant. Read more
FDA issues complete response letter for omecamtiv mecarbil
The FDA has issued a complete response letter to Cytokinetics for omecamtiv mecarbil, an investigational, selective small molecule cardiac myosin activator for treatment of HFrEF, according to a press release. Read more
500 extra steps per day could reduce CV risk for adults 70 years and older
For every 500 extra steps per day, or an additional one-quarter mile walked, adults aged 70 years or older could reduce risk for a CVD event by approximately 14%. Read more
Where do we go from CLEAR?
In the past decade, there have been major advances in lipid-lowering therapeutics, and another was made apparent in March at the American College of Cardiology Scientific Session. Read more
Statins may prevent cardiac dysfunction in patients taking anthracyclines
In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma. Read more
Pulsed field ablation for AF safe, effective at 1 year
In the PULSED AF pivotal trial, pulsed field ablation of symptomatic atrial fibrillation yielded a low rate of adverse events and demonstrated effectiveness consistent with established ablation strategies at 1 year. Read more
Return-to-play protocol ‘essential’ for elite athletes at risk for sudden cardiac death
Elite athletes with genetic risk for sudden cardiac death can safely return to play with a shared decision-making model that includes careful evaluation, risk stratification and tailoring of genetic heart disease therapy. Read more
Data suggest Apple Watch appropriate for AF screening, but not disease management
An Apple Watch feature designed to detect AF was associated with a low rate of false-positive detections but only modest sensitivity for detections in people with a history of AF, researchers reported. Read more
Collapse
Healio Coverage
Click Here to Manage Email Alerts